MedTrace Logo

International Registry for Patients With Castleman Disease

NCT02817997 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2026-03-03

No results posted yet for this study

Summary

The purpose of this study is to collect clinical, laboratory, and patient survey data from patients with Castleman disease to improve understanding, diagnosis, and treatment of the disease. Funding source - FDA OOPD.

Conditions

  • Castleman Disease
  • Castleman's Disease
  • Giant Lymph Node Hyperplasia
  • Angiofollicular Lymph Hyperplasia
  • Angiofollicular Lymph Node Hyperplasia
  • Angiofollicular Lymphoid Hyperplasia
  • GLNH
  • Hyperplasia, Giant Lymph Node
  • Lymph Node Hyperplasia, Giant

Sponsors & Collaborators

  • EUSA Pharma, Inc.

    collaborator INDUSTRY

  • Castleman Disease Collaborative Network

    collaborator OTHER

  • University of Pennsylvania

    lead OTHER

Principal Investigators

  • Joshua Brandstadter, MD, PhD, MSc · University of Pennsylvania

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2027-09-30
Completion
2027-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02817997 on ClinicalTrials.gov